Has Ammar Bayrakdar, MD received payments from drug or device companies?

Yes. Drug and device makers reported $517,329 in general payments to Ammar Bayrakdar, MD across 1,216 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Ammar Bayrakdar, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Ammar Bayrakdar, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Ammar Bayrakdar, MD

Endocrinology, Diabetes & Metabolism · Evergreen Park, ILNPI 1841243334

Payments from drug & device makers

$517,329in general payments, 2019–2025

Across 1,216 payments — averaging $425.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Novo Nordisk$335K
Merck$54K
Lilly USA, LLC$43K
Boehringer Ingelheim$42K
Johnson & Johnson$22K
Bayer$6K
plus $14K from 54 others

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Novo Nordisk	411	$335,333
Merck	71	$54,359
Lilly USA, LLC	106	$43,118
Boehringer Ingelheim	94	$42,365
Johnson & Johnson	43	$21,874
Bayer	23	$6,005
Abbott	17	$2,578
Insulet Corporation	34	$1,244
AstraZeneca	45	$942
Mannkind Corporation	37	$893
Sanofi-aventis U.S. LLC	32	$867
Amgen(2 entities)	30	$803
Xeris Pharmaceuticals, Inc.	32	$735
Dexcom, Inc.	16	$529
Corcept Therapeutics	22	$520
BD	7	$477
Preventric Diagnostics, Inc.	1	$395
AbbVie(2 entities)	16	$339
Novartis	15	$337
Intuity Medical Inc	7	$306
Radius Health, Inc.	10	$257
Amarin Pharma, Inc.	13	$241
Tandem Diabetes Care, Inc.	5	$199
Recordati_rare_diseases_inc.	6	$150
Astellas Pharma US Inc	7	$133
Neurocrine Biosciences, Inc.	4	$129
Ultragenyx Pharmaceutical Inc.	6	$126
IBSA Pharma Inc.	7	$113
BETA Bionics, Inc.	6	$107
Nestle Healthcare Nutrition Inc.	7	$106
Cequr Corporation	2	$100
Pfizer	3	$92
Senseonics, Incorporated	1	$86
Sequel Med Tech, LLC	3	$82
Ascensia Diabetes Care US Inc.	4	$82
Amryt Pharma Holdings Ltd	4	$74
Exact Sciences	4	$72
Halozyme Inc	4	$68
Antares Pharma, Inc.	4	$60
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC	4	$58
Clarus Therapeutics Inc.	4	$57
Ascendis Pharma Endocrinology Inc	3	$56
Teva Pharmaceuticals USA, Inc.	3	$55
GSK	3	$53
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)	2	$49
Biohaven Pharmaceutical Holding Company Ltd.	2	$47
Lundbeck LLC	2	$45
Kyowa Kirin, Inc.	2	$45
Genentech USA, Inc.	2	$43
Medtronic	2	$42
Amneal Pharmaceuticals LLC	2	$30
Boston Scientific	1	$29
Ironwood Pharmaceuticals, Inc	2	$28
Edwards Lifesciences	1	$28
Medline Industries LP	2	$27
Otsuka America Pharmaceutical, Inc.	1	$26
Hikma Pharmaceuticals USA	2	$26
Madrigal Pharmaceuticals	1	$25
Chiesi USA, Inc.	1	$22
Biohaven Pharmaceuticals, Inc.	1	$22

How this compares

$517,329 in reported general payments places this provider in the 95th percentile of 347 endocrinology, diabetes & metabolism providers in Illinois.

See all endocrinology, diabetes & metabolism providers in Illinois →

Medicare billing

Part B allowed, 2024

$232,068

Medicare patients

544

Services billed

5,987

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other endocrinology, diabetes & metabolism in Evergreen Park

Abdallah AltarshanEvergreen Park$132K
Liana BillingsSkokie$3.4M
Leon FogelfeldChicago$1.5M
Grazia AleppoChicago$1.4M
Wahid KassarChicago$884K
Anthony PickLake Forest$665K
Hiralal MaheshwariMcHenry$642K
Wenyu HuangChicago$639K
Babak PazookiJoliet$582K
Silvana PannainChicago$575K

See the full list for Illinois →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →